Varenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized Trial

Schizophrenic patients have a high rate of smoking and cognitive deficits which may be related to a decreased number or responsiveness of nicotinic receptors in their brains. Varenicline is a partial nicotinic agonist which is effective as an antismoking drug in cigarette smokers, although concerns...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS One
Päätekijät: Smith, Robert C., Amiaz, Revital, Si, Tian-Mei, Maayan, Lawrence, Jin, Hua, Boules, Sylvia, Sershen, Henry, Li, Chunbo, Ren, Juanjuan, Liu, Yanhong, Youseff, Mary, Lajtha, Abel, Guidotti, Alessandro, Weiser, Mark, Davis, John M.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2016
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4701439/
https://ncbi.nlm.nih.gov/pubmed/26730716
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0143490
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia